Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | HNF4A | P41235 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132986 | 1.00 | BCAT2 (1.00) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Methane SCHEMBL27520060 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28275782 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28355265 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1785690 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27487444 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Urea SCHEMBL28572437 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5180095 | 0.98 | BCAT2 (0.96) | BCAT2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31140008 | 0.96 | BCAT2 (0.92) | BCAT2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16149659 | 0.95 | BCAT2 (0.91) | BCAT2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716529-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2024243343-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | KARANICOLAS JOHN (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-07 | — | — | US | disclosed |
| EP-4440560-A1 | SMALL MOLECULE INHIBITORS OF REPEAT ASSOCIATED NON-AUG (RAN) TRANSLATION AND COMBINATION THERAPIES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023102111-A1 | SMALL MOLECULE INHIBITORS OF REPEAT ASSOCIATED NON-AUG (RAN) TRANSLATION AND COMBINATION THERAPIES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220072142-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | BCAT2 3326/4885NPC1 2849/4885RAB9A 2048/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | BCAT2 3326/4885NPC1 2849/4885RAB9A 2048/4885 |
| US-20220072142-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT | ASH1L, ASH2L, CHD1L | BCAT2 2716/4885NPC1 2892/4885RAB9A 2176/4885 |
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | BCAT2 3326/4885NPC1 2849/4885RAB9A 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.